PPARG and amyotrophic lateral sclerosis: Synthetic PPAR-γ agonists developed in the past 25 yearsthat are used primarily as antidiabetic drugs are suitable candidates and areindispensable to study the role of PPAR-γ in ALS which may potentially lead to beneficialeffects in ALS patients.